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Abstract
Purpose Intravenous IgG (IVIG) treatment wear-off is com-
monly experienced by patients, who report increased suscep-
tibility to infection, and decreased quality of life towards the
end of their 3- or 4-week dosing cycle, when serum IgG levels
approach their trough. We quantified IVIG wear-off in terms
of treatment efficacy and patient well-being.
Methods Data were collected from patients enrolled in three
Phase III trials of Sandoglobulin® NF Liquid or Privigen®,
treated every 3- or 4- weeks. Pooled analyses of raw patient
data compared the rate of infection and other clinical out-
comes during the course of the dosing cycle. Subjective symp-
toms of wear-off were quantified by comparing patient-
reported overall well-being scores.
Results The probability of a first infection in the final week of
the IVIG cycle was 1.26 (95 % confidence intervals [CI]:
0.76–2.11; p = 0.3621) and 1.55 (95 % CI: 1.04–2.32;
p = 0.0314) times higher than in the first week, for patients
on a 3-week cycle and 4-week dosing cycles, respectively.
Wear-off, as manifested by a decrease in overall well-being,
was experienced in 10 % of all cycles and reported at least
once by 61 % of the patients on a 3-week cycle, and 43 % of
those on a 4-week cycle.
Conclusions These findings confirm the existence of de-
creased efficacy (treatment wear-off) towards the end of a 3–
4 week IVIG dosing cycle, and provide a quantifiable evalu-
ation to a phenomenon typically reported anecdotally. For
patients experiencing wear-off, increasing the IgG dose or
shortening the dosing interval and/or a switch to SCIG may
be beneficial.
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Introduction
Patients with antibody deficiency, a subclass of primary im-
munodeficiencies (PID), are predisposed to recurrent and per-
sistent infections, requiring life-long, regular infusions of IgG
to provide protection [1–3]. Intravenous IgG (IVIG) adminis-
tered every 3- or 4- weeks has been the standard of care for
patients with PID since the 1980s [4].
Infusion intervals of up to a month appear feasible due to
IgG having a plasma half-life of approximately 26–41 days
[5–8]. The IVIG infusion leads to a high peak in serum IgG
concentration right after the end of infusion, followed by a
rapid fall in the subsequent 48 h, and a slower decline over
the next 30 days [9]. Amore recently established alternative to
IVIG is subcutaneous IgG (SCIG) [10]. SCIG is typically
administered at more frequent intervals (daily to biweekly
[every 2 weeks]), but infrequent dosing (up to every 4 weeks)
is feasible with hyaluronidase facilitated SCIG (fSCIG) [11,
12]. Compared with IVIG, fSCIG does not produce a high
post-infusion peak, but from the secondweek onwards decline
in plasma IgG levels is similar (Fig. 1) [11, 12]. By contrast,
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frequent SCIG administration provides stable, ‘steady-state’,
plasma IgG levels throughout the dosing cycle.
The Bwear-off^ effect in immune replacement therapy re-
fers to the experience of diminished treatment efficacy to-
wards the end of the 3–4 week IVIG treatment cycle, when
serum IgG concentration may fall below a protective level.
During this period, patients report an increased susceptibility
to infection and a decrease in quality of life, clinically mani-
festing as general malaise, fatigue, arthralgia, and myalgias
[9]. Wear-off is a common experience amongst patients. In
the only survey we are aware to report the subjective feelings
of wear-off (conducted in 2003), 42 % of the 1186 patients
with PID reported feeling the effects of the infusion wearing
off by the end of the treatment cycle as a typical experience of
their therapy, while a further 26 % reported feeling wear-off
occasionally [13].
Although acknowledged, accounts of wear-off effect are
largely anecdotal, with few studies on this subject having been
conducted to date. The aim of this investigation was to quan-
tify the objective and subjective signs and symptoms of wear-
off effect towards the end of the treatment cycle.
Methods
Patient Population
Results of three Phase III clinical trials of Sandoglobulin® NF
Liquid (product no longer available, CSL Behring AG, Berne,
Switzerland; NCT00168012) or Privigen® (CSL Behring AG,
Berne, Switzerland; NCT00168025, NCT00322556) deliv-
ered every 3- or 4-weeks by intravenous administration were
included in these pooled analyses. These multicenter trials
were conducted in the United States and Canada (from
September 2004 to January 2007). In all trials, the dosing
interval was the same as the patients’ previous IVIG therapy,
which had been selected as per standard of care, based upon
their clinical response. Data from 130 patients with 7482 data
points were used for the infection analysis, and data from 119
patients with 23,560 data points for the analysis of overall
well-being. Demographic characteristics of patients enrolled
in these studies are shown in Table 1.
All patients participating in the studies analysed here pro-
vided written informed consent. Approval from institutional
review boards was obtained prior to the start of the studies.
Study Endpoints
All endpoints and methods of their evaluation in the
original studies were prespecified in the respective study
protocols. The results reported here are from a post hoc
retrospective pooled analysis of raw patient data.
The following clinical treatment efficacy endpoints were
evaluated per week of the dosing cycle: 1) first occurrence
of infection; 2) number of days with infection; 3) number of
days hospitalized; 4) number of days off work/school; 5) num-
ber of days with fatigue.
Infections were identified in the study records as ad-
verse events (AEs) with the system organ class “infec-
tions and infestations”, according to the Medical
Dictionary for Regulatory Activities (MedDRA), current
Version 18.0. Fatigue was identified by a search in the
AE listings as any AE including the term Bfatigue^. The
number of days out of work/school was measured as the
number of days out of work/school/kindergarten/day
care or unable to perform normal activities due to the
underlying PID or infection. The number of days hos-
pitalized was assessed as the number of days hospital-
ized due to the underlying PID. Events for days out of
work/school and days of hospitalization were recorded
in patient diaries, which patients completed during their
study participation. All patient data collected from Day
1 of the study until 48–96 h after the last infusion of
the study, were used in the analyses. Patients were ad-
vised that a missing entry in the diary would be
interpreted as no event. If the diary was not provided,
the data were to be considered missing, but such case
was not recorded for any of the diary data endpoints.
Subjective symptoms of wear-off were quantified by mea-
suring the overall well-being of 119 patients enrolled in the
studies NCT00168012 and NCT00168025. Of these patients,
33 were on a 3-week cycle and 86 on a 4-week cycle,
representing a total number of 315 and 615 dosing cycles,
respectively. Patients recorded daily their perception of overall
well-being on a scale of 1–5, in which a score of 1 equated to
very poor; 2, poor; 3, fair; 4, well; and a score of 5, very well.
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Fig. 1 Serum IgG concentration following treatment by IVIG, SCIG and
fSCIG. Representative pharmacokinetic serum concentration over time
for a patient, comparing a 4-week intravenous infusion of IG (IGIV) with
a weekly subcutaneous infusion at 143 % of the intravenous dose (IGSC)
and a 4-week hyaluronidase facilitated SCIG dose at 104 % of the
intravenous dose (IGHy). Area under the concentration curve (AUC)
values are normalized to IGIV. Figure reproduced from fig. 5 in
Wasserman et al. 2014 (adapted from fig. 1 in Wasserman et al. 2012),
with kind permission of Elesevier Inc. [11, 12]
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The clinical studies analyzed in this study were completed
before the FDA guidance on patient-reported outcomes devel-
opment (2009) [14] was published. To determine what could
be considered a meaningful change in well-being score, a data
variance analysis was performed. A drop of ≥1 point was
considered clinically relevant, as it is approximately twice
larger than between- or within-patient variance (0.403 and
0.437 for 3-week and 4-week regimens and 0.745 (3 week
regimen) and 0.435 (4-week regimen), respectively).
Statistical Analysis
Objective wear-off endpoints were analyzed by treat-
ment cycle week using a generalized linear model for
repeated count data within unique patients and com-
pound symmetry correlation structure without any co-
variates. The actual time between infusions was
accounted for in the model. Distribution analysis was
performed using quasi-likelihood under the indepen-
dence model criterion (QIC) [15].
Best fitting models were used to estimate the proba-
bility of a first infection and the number of days with
fatigue, infection, hospitalization, and absence from
work/school per week within the treatment cycle. The
corresponding risk ratios vs. Week 1 were calculated.
Analyses for the probabilities of infection, days off
and hospitalization were additionally performed with
time intervals shifted by 3 days (Week 1 covers Days
3–9; Week 2 covers Days 10–16; Week 3 covers Days
17–23; and Week 4 covers Days 24–31) based on the
hypothesis that the average incubation period of the
most common respiratory infections is approximately
3 days [16]. Binomial distribution was found to fit best
for probability of first occurrence of infection, negative
binomial distribution gave the best fit for the probability
of number of days with infection and number of days
with fatigue, and the Poisson distribution gave the best
fit for probability of number of days hospitalized and
number of days off work/school, per week of the treat-
ment cycle. The impact of median IgG trough levels
during study, categorical patient age (2–11, 12–15, 16–
64, and ≥65 years), PID diagnosis (X-linked agamma-
globulinemia [XLA] versus common variable immuno-
deficiency [CVID]), and presence or absence of bron-
chiectasis at study entrance, was evaluated in relation to
the study endpoints using a generalized linear model for
repeated measures.
Overall well-being scores were analyzed using de-
scriptive statistics. Patient reported wear-off (as
manifested by decreased well-being) was defined for
every patient as a drop in overall well-being of ≥1 on
>3 days of the last week of a dosing cycle compared
with the mean score recorded in Week 2. No imputation
was performed for missing data for overall well-being.
A total of 8 out of 23,568 data points (0.034 %) in 3
patients were missing. The influence of these missing
data points was considered extremely low and thus ex-
cluded from analysis.
Table 1 Demographic characteristics of patients from the pooled analysisa
Clinical study (ID) Sandoglobulin® NF liquid
(NCT00168012)
Privigen®
(NCT00168025)
Privigen®
(NCT00322556)
Total number of patients 42 80 55
Indication, n (%)
CVID 32 (76.2) 59 (73.8) 44 (80.0)
XLA 10 (23.8) 21 (26.3) 11 (20.0)
Gender, n (%)
Female 13 (31.0) 34 (42.5) 29 (52.7)
Male 29 (69.0) 46 (57.5) 26 (47.3)
Age (years), mean (SD) 32.2 (18.3) 28.2 (19.3) 29.9 (20.8)
BMI (kg/m2), mean (SD) 22.5 (5.1)
(n = 38)
23.5 (6.3)
(n = 80)
24.5 (7.8)
(n = 53)
Duration of PIDb (years),
mean (SD)
10.9 (8.8) 8.6 (7.5) 8.12 (6.8)
IgG trough level (g/L),
mean (SD)
9.95 (2.69)
(n = 41)
9.40 (2.75)
(n = 79)
9.72 (2.23)
(n = 54)
Median weekly dose (mg/kg) 125.5 117.8 128.2
BMI body mass index, CVID common variable immunodeficiency, PID primary immunodeficiency, SD standard deviation, XLA X-linked
agammaglobulinemia
a Data for well-being are available only for a subset of patients
b Prior to study entry
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No adjustment of p-values for multiplicity was done in this
post hoc analysis.
Results
Patient Population
Data were collated from three Phase III clinical trials of IVIG
therapy in patients with PID providing a total sample size
larger than the majority of single studies in patients with PID.
The majority of patients in each of the three studies was
diagnosed as having CVID, and on average the duration of
PID before study entry was 8–11 years. Patients on a 3-
week cycle had only slightly higher average serum IgG trough
levels, although they received notably higher average weekly
IgG doses than those on a 4-week cycle (Table 2). The median
number of dosing cycles recorded in the study was 7 (range:
1–38) for the 3-week cycle, and 6 (range: 1–31) for the 4-
week cycle. The median number of dosing cycles for the set
of 119 patients for which overall well-being scores were
assessed, was 8 (range: 3–15) for the 3-week cycle, and 8
(range: 1–12) for the 4-week cycle.
Occurrence of Infection
The most common infections experienced by patients were
sinusitis, nasopharyngitis and upper respiratory tract infec-
tions. The probability of a first infection during a dosing cycle
was significantly increased in the last week of the 4-week
dosing cycle. There was also an increased probability of a first
infection in the last week of the 3-week dosing cycle, although
this did not reach statistical significance (Fig. 2). Compared
with Week 1, the risk ratio for a first infection during the final
cycle week was 1.26 (p = 0.3621; 95 % confidence interval
[CI] 0.762, 2.105) and 1.55 (p = 0.0314; CI 1.04, 2.316) for
patients on 3- and 4-week dosing schedules, respectively. A
generalized linear model for repeated measures showed that
higher IgG trough levels were associated with a slightly in-
creased risk for infections throughout the cycle (p = 0.034 for
3-week and p = 0.26 for 4-week dosing cycles). Among pa-
tients on a 4-week dosing cycle, those with a diagnosis of
CVID were also at increased risk for infections (p = 0.003).
However, these factors had only a minimal impact on the risk
ratio for infection in the final week compared with Week 1.
The probability of days with infection was signifi-
cantly lower in the second and third weeks of the 3-
and 4- week dosing cycles, respectively (Fig. 3a–c).
Shifted time interval analysis (accounting for the aver-
age incubation period of infection) showed that the
probability of infection was greatest during the last
week of the cycle for both 3- and 4- week cycles, with
a significantly greater risk compared with Week 1 (1.13,
p = 0.0474, and 1.13, p = 0.0004, times, respectively)
(Fig. 3d–f).
Fatigue
The probability of fatigue was greatest in the first week of both
the 3- and 4-week dosing cycles, and was significantly lower
in the subsequent weeks of the treatment cycle (Fig. 4).
ComparedwithWeek 1, the risk ratio for fatigue in subsequent
weeks was at most 0.595 (p < 0.0001) and 0.367 (p = 0.0170)
for patients on 3- and 4-week dosing schedules, respectively.
Hospitalization or Absence from Work/School
The average number of days with hospitalization or
days off work/school were not significantly different
across the cycle weeks for either dosing cycle. The
number of events (days/patient/week) for hospitalization
for each week of the cycle ranged from 0.005 to 0.024
and from 0.028 to 0.048 for 3- and 4- week dosing
cycles, respectively. The corresponding values for days
off work/school were 0.274–0.358 and 0.114–0.191, re-
spectively. A generalized linear model for repeated mea-
sures suggests that patients diagnosed with CVID have
more days with hospitalization and/or days off work/
school than those patients diagnosed with XLA.
Additionally, patients with bronchiectasis on a 4-week
dosing cycle had a higher probability of experiencing
days off work/school etc. (unable to perform normal
daily activities), compared with patients without comor-
bidity of bronchiectasis (p = 0.0159 for unshifted anal-
ysis and p = 0.0169 for analysis shifted by 3 days).
Table 2 Comparison of IgG
trough levels for 3- and 4-week
dosing cycles
3-week cycle 4-week cycle
Mean (SD) Minimum Maximum Mean (SD) Minimum Maximum
Median weekly dose
(mg/kg)
168.1
(48.61)
95.2 266.7 118.70
(33.91)
50 222.0
Median IgG trough level
(g/L)
10.8 (2.91) 5.5 18.0 9.2 (2.3) 4.9 21.9
SD, standard deviation
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Patients’ Overall Well-Being
Scores for overall well-being amongst the study patients indi-
cated a general feeling of being ‘well’ for patients on both 3-
week and 4-week IVIG dosing cycles (Fig. 5a). Patients on a
4-week dosing cycle had, on average, higher overall well-be-
ing, but the course of change was similar between the dosing
cycles, with the lowest values registered during the last pre-
infusion week of the dosing schedule. After dosing, there were
daily score increases until Day 5, from 3.5 to 3.8 (3-week cy-
cle) and from 3.8 to 4 (4-week cycle). Scores then remained
stable until the end of Week 2, whereupon there was a steady
drop until the end of the cycle to 3.7 and 3.8 for patients on 3-
week and 4-week cycles, respectively (unadjusted p-value
from paired t-test 0.0001 for both schedules).
Twenty patients on a 3-week cycle (61 %) and 37 patients
on a 4-week cycle (43 %) reported symptoms of wear-off at
least once, as defined by a drop in overall well-being score of
≥1 point on >3 days of a dosing cycle’s last week compared
with the mean score recorded in Week 2. Wear-off, as mani-
fested by well-being decrease, was reported in 10 % of all
cycles. Summarizing these cycles, patients on a 3-week cycle
experienced a steady increase in overall well-being from 3.6 to
4.1 by Day 9, and then a sharp decline to 2.5 by Day 18
(Fig. 5b). For patients on a 4-week cycle, there was steady
score increase from 3.8 after dosing to 4.2 by Day 5. Scores
remained stable until the end of Week 2 and then decreased
rapidly to 2.8 in the final week of the cycle. Mean overall well-
being decreases of 1.2 were recorded fromWeek 2 to the final
week of the dosing cycle for both the 3- and 4-week cycles
(p < 0.0001) (Fig. 5d and e).
Among patients who did not experience wear-off, there
was a slight increase in overall well-being in the 3–4 first days
of the cycle (Fig. 5b), thereafter, no characteristic change was
seen.
Discussion
The aim of IgG therapy is to protect patients with PID against
infections by providing adequate serum and tissue concentra-
tions of IgG. However, a universal protective IgG concentra-
tion does not exist and varies from individual to individual
depending on a number of internal and external factors. The
term Bbiologic IgG level^was coined to reflect an individual’s
protective IgG concentration [17] and it is the aim of the
treatment to identify and maintain IgG concentrations above
this level. In healthy adults, 7 g/L represents a value within the
normal plasma IgG range (6–16 g/L) and is, therefore, often
considered to be associated with reasonable protection against
infection in many immunocompetent individuals and patients
with PID [18–20]. As IgG concentrations decline during the
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IVIG dosing cycle, patients report a feeling of treatment wear-
off towards the end of their cycle, which may reflect IgG
concentrations dropping below biologic levels.
In quantifying objective wear-off outcomes, we found that
the first occurrence of infection and number of days with
infection per week of IVIG infusion cycle, provided a useful
objective measure for the efficacy of therapy at each stage
(week) of the treatment cycle. During the final week of the
treatment cycle, when serum IgG levels approached their
trough, the probability of infection increased for PID patients
on both 3- and 4-week dosing cycles.
We also noted that infections appeared to be more frequent
during the 3 days following the infusion than the rest of Week
1 and Week 2. This led to the hypothesis that these infections
might have started developing just before the next IVIG infu-
sion, since common infections have an incubation period of a
few days. We tested this hypothesis by performing a ‘shifted’
analysis (i.e. the days of infection were shifted by 3 days).
These analyses showed a clearer accumulation of infections
during the final week of the dosing cycle, supporting the no-
tion that when analyzing wear-off effect, reasonable incuba-
tion periods of infection should be taken into consideration.
A generalized linear model for repeated measures, includ-
ing median IgG trough levels as a covariate, found that pa-
tients with higher trough levels tended to have slightly more
infections. A possible explanation is that patients with more
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severe PID condition received higher doses of IgG therapy,
leading to higher trough levels. However, their individual
protective serum IgG levels (Bbiologic levels^ according to
Bonagura et al. [17] were apparently higher as well).
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Objective signs of wear-off in the last pre-infusion week
were not observed for number of days off work/school, or
number of days of hospitalization. These events were rare
and therefore less informative for the purposes of this analysis.
In the absence of a standard measure of patient re-
ported wear-off, using an overall well-being endpoint,
we introduced a conservative threshold of well-being
declining by at least 1 point on the 5-grade scale. The
observed within-patient and between-patient data vari-
ances suggest this value to be a conservative threshold.
With respect to patients’ subjective perception of treat-
ment wear-off defined this way, results from daily re-
cords have indicated that 42 % of patients experienced
the feeling of wear-off in the second half of the dosing
cycle on a regular basis [13]. We found that patient-
reported overall well-being proved to be an important
quantitative indicator of treatment wear-off effect. A
measurable decline in well-being was experienced by
patients during the final week of the dosing cycle. On
average wear-off was experienced in 10 % of all cycles,
suggesting that wear-off, or its perception, is influenced
by factors beyond serum IgG levels, including random
events such as exposure to infectious agents. For those
on a 4-week cycle, this decline appears to originate
from the second half of the third week. In patients
experiencing wear-off, some improvement was observed
a few days before the next infusion, which is difficult to
explain, unless it is a psychological effect of the im-
provement expected with the upcoming infusion.
In addition to measuring wear-off, patients’ percep-
tion of well-being also reflects the impact of receiving
an IVIG infusion: reported well-being was lowest just
after the administration of IVIG, improving over the
next 2–3 days. This most likely reflects the impact of
known systemic AEs of IVIG therapy, associated with
peak serum protein concentration immediately after
IVIG infusion (fever, headache, and nausea) [9, 21].
Alternatively, the low well-being in the first week of
the cycle may be a delayed result of an infection expe-
rienced during the previous week, but this would be
difficult to evaluate. Of note, study patients included
in this analysis had a broad range of median IgG trough
levels (4.9–21.9 g/L; Table 2), extending beyond the
lower and upper thresholds of the normal plasma IgG
range (6–16 g/L [18–20]); this observation reflects the
efforts to achieve individual protective IgG concentra-
tions and thus minimize the risk of infections.
Fatigue is another adverse event commonly associat-
ed with IVIG infusion [21]. It is therefore unsurprising
that fatigue was most likely to be experienced during
the first week post IVIG infusion in an unshifted
anlaysis. Fatigue has been described as a sign of
wear-off [9]. However, the present investigation does
not support this hypothesis, as an increase in the inci-
dence of fatigue towards the end of the cycle was not
observed.
Overall, results from our analyses illustrate that patients
with PID on IVIG therapy regularly experienced decreased
feeling of overall well-being on both ends of the dosing cycle:
for the first several days right after the IVIG infusion (likely
due to a combination of side effects of IVIG and infections
carrying over from the previous cycle), and during the last
week of the dosing cycle (wear-off).
Wear-off has also been reported during the use of IVIG to
treat neurologic diseases. Neurologists have anecdotally re-
ported patients experiencing diminished strength and ability
to perform daily tasks towards the end of their dosing cycles
[22]. In a case report of a patient with multifocal motor neu-
ropathy, sharp fluctuations in strength (Medical Research
Council score for muscle strength) were observed during the
4-week cycle, with strength peaking after each infusion [23].
Subsequently, strength was stabilized after the patient was
switched to weekly SCIG infusions.
A limitation of this study is that it represents a retrospective
pooled analysis of data from several trials. Prospective trials
would be warranted to confirm the results presented here. On
the other hand, pooling retrospective data into a combined
dataset allowed using a higher number of patients and data
points than a single PID study can provide, and inspires con-
fidence that the analyses reported here can be considered
conclusive.
Allocation of patients to a 3- or 4-week dosing cycle
was based on physicians’ clinical judgment and reflects
standard clinical practice. Patients on a 3-week cycle
received approximately 40 % higher doses than those
on a 4-week cycle (weekly equivalent of the mean of
median doses of 168.1 mg/kg vs. 118.7 mg/kg, respec-
tively), but the IgG trough levels were only slightly
higher (mean of median troughs at 10.8 g/L and
9.2 g/L, respectively), suggesting that patients on a 3-
week cycle were metabolizing IgG faster. In these pa-
tients, the overall numbers of first infections, days with
infection, and the probability of infection were also
higher, suggesting that they were more vulnerable to
infection. Therefore, it appears that the higher IVIG
doses and resulting higher serum IgG levels experienced
by these patients did not ensure the same protection
against infections compared with the 4-week dosing
group. Consistent with these observations, patients on
a 3-week cycle reported a lower degree of well-being
throughout the cycle and experienced a sharper decrease
in overall well-being at the end of the dosing cycle than
those receiving IVIG on a 4-week cycle. A higher pro-
portion of these patients experienced patient-reported
wear-off, when compared with patients on a 4-week cy-
cle. It is likely that patients were assigned to a 3-week
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dosing cycle owing to greater PID severity. However,
this strategy appears to have been only partially suc-
cessful. A solution for avoiding wear-off would be to
decrease the IVIG dosing interval to less than 3 weeks.
However, this may not be convenient for patients re-
ceiving IVIG administration at a hospital or clinic, and
would incur increased healthcare costs as a conse-
quence. More frequent SCIG infusions – daily, several
times per week, weekly, or biweekly – offer a conve-
nient alternative, which can be administered at home (it
is worth noting that IVIG can also be administered at
home, but this is not a popular option in many coun-
tries, and it usually requires visit of a home infusion
nurse). Dividing the single monthly IgG dose into
smaller, but more frequently administered doses, results
in more stable serum IgG levels with reduced
peak/trough variation [5, 9, 24]. As a result, patients
do not experience diminished serum IgG levels towards
the end of their dosing cycle, and consequently should
not be subject to treatment wear-off. Although there is
no direct evidence of the wear-off effect for the recently
introduced treatment modality of fSCIG (characterized
by typical IVIG infusion cycles every 3–4 weeks [11])
it would be important to study if the IVIG-like pharma-
cokinetic features of this therapy are also associated
with symptoms or signs of wear-off.
Through this study we have been able to quantify the
wear-off effect in terms of both clinical response (in-
creased frequency of a first infection during the last
week of the IVIG cycle, and increased number of infec-
tion days during this period) and patient perception
(successive drop in overall well-being during the final
week of the IVIG cycle). Both clinical and patient-
reported outcomes of wear-off appear to be associated
with the dropping IgG concentration at the end of the
dosing cycle.
Conclusions
Pooled data analyses allowed quantifying the objective
and subjective symptoms and signs of IVIG treatment
wear-off effect. For patients experiencing wear-off, in-
creasing the IgG dose, shortening the dosing interval,
and/or a switch to SCIG may be beneficial.
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